Research and Development

Research and Development

Taro is a research-driven international pharmaceutical company that was established on the principle that research and development would be the cornerstone of its growth strategy.  

Taro's R&D centers are located in Haifa bay (Israel), Brampton (Canada) and Hawthorne, New York (USA).
The two main development centers (Israel and Canada) include formulation and analytical development laboratories with state-of-the-art equipment, while the center in Israel houses also synthetic organic chemistry laboratories for active pharmaceutical ingredients (API) development.

Our researchers ensure optimal API and product formulation development including analytical methods, stability testing and in-vitro specialized techniques. Taro's clinical capabilities include bioequivalence studies and a variety of clinical end point studies from pre-clinical up to phase III and IV studies. These are closely managed from protocol preparation throughout the final reports.

Our generic R&D includes developments of oral solid-based immediate release to complex modified released OSDs (tablets and capsules), liquids (solutions, suspensions) and dermatological semi solids topical formulations (creams, ointments, lotions, gels, and foams).
As a leader in the topical generic products our innovative R&D is also focused on the dermatological therapeutic area.

We develop products for a wide range of dermatologic disorders having unmet needs. These innovative developments are all secured with our own intellectual property.
Over the years we have developed in addition to our Rx line, a vast number of over-the-counter products for a variety of dermatological and other diseases.

Our R&D centers work in close conjunction with our Regulatory Affairs departments to support global submission of the generic and branded products in US, Canada, Israel, Europe and other markets. 

Providing quality products through scientific innovations, diligence and precision is the goal of all of Taro's research programs.